Linked Life Data

2831806

Source:http://linkedlifedata.com/resource/pubmed/id/2831806

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1988-4-11
pubmed:abstractText
3'-Azido-2',3'-dideoxythymidine (AZT) has been administered to 7 patients with human immunodeficiency virus-associated neurological disease: 3 with dementia, 2 with peripheral neuropathy, 1 with dementia and peripheral neuropathy, and 1 with T-10 paraplegia. Six of the patients showed improvement in their neurological dysfunction on being administered AZT, as assessed by clinical evaluation, neuropsychological testing, nerve conduction studies, and/or positron emission tomographic scans. Three of these 6 patients showed sustained improvement 5 to 18 months after the initiation of AZT therapy. These results suggest that certain human immunodeficiency virus-associated neurological abnormalities are at least partially reversible following the administration of antiretroviral therapy and provide a rationale for further studies using antiretroviral chemotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0364-5134
pubmed:author
pubmed:issnType
Print
pubmed:volume
23 Suppl
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
S82-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease.
pubmed:affiliation
National Cancer Institute, Bethesda, MD 20892.
pubmed:publicationType
Journal Article, Clinical Trial